Bank of New York Mellon Corp lowered its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 2.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,959,884 shares of the company's stock after selling 47,745 shares during the period. Bank of New York Mellon Corp owned approximately 0.39% of Elanco Animal Health worth $20,579,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of ELAN. FMR LLC lifted its holdings in shares of Elanco Animal Health by 1,153.6% during the 4th quarter. FMR LLC now owns 40,232,327 shares of the company's stock worth $487,213,000 after acquiring an additional 37,022,891 shares during the period. Norges Bank bought a new stake in shares of Elanco Animal Health during the 4th quarter worth approximately $47,424,000. Freestone Grove Partners LP bought a new stake in shares of Elanco Animal Health during the 4th quarter worth approximately $20,396,000. Magnetar Financial LLC lifted its holdings in shares of Elanco Animal Health by 13.7% during the 4th quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock worth $145,711,000 after acquiring an additional 1,454,082 shares during the period. Finally, Prudential Financial Inc. lifted its holdings in shares of Elanco Animal Health by 40.4% during the 4th quarter. Prudential Financial Inc. now owns 4,224,997 shares of the company's stock worth $51,165,000 after acquiring an additional 1,214,992 shares during the period. Institutional investors own 97.48% of the company's stock.
Elanco Animal Health Trading Down 0.8%
NYSE ELAN traded down $0.12 on Monday, hitting $14.67. The company's stock had a trading volume of 3,551,782 shares, compared to its average volume of 5,028,103. The company has a quick ratio of 1.46, a current ratio of 2.71 and a debt-to-equity ratio of 0.68. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $15.78. The company's 50-day moving average is $13.82 and its 200 day moving average is $11.79. The firm has a market cap of $7.28 billion, a PE ratio of 19.82, a PEG ratio of 2.88 and a beta of 1.67.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The firm had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.17 billion. During the same period in the prior year, the company posted $0.34 EPS. The company's revenue was down 1.0% on a year-over-year basis. As a group, analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on ELAN. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective for the company in a research report on Thursday. Finally, Stifel Nicolaus upped their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Elanco Animal Health has a consensus rating of "Moderate Buy" and a consensus target price of $16.00.
Check Out Our Latest Report on Elanco Animal Health
About Elanco Animal Health
(
Free Report)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
See Also

Before you consider Elanco Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.
While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.